Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
NCT ID: NCT01901146
Last Updated: 2019-08-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
725 participants
INTERVENTIONAL
2013-04-29
2017-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
NCT01160211
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
NCT01998906
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01989676
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
NCT03304080
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
NCT00503750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABP 980
Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.
ABP 980
ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Paclitaxel
Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
Trastuzumab
Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase.
Trastuzumab
Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Paclitaxel
Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABP 980
ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Trastuzumab
Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Paclitaxel
Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed invasive breast cancer
* Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection
* Planning neoadjuvant chemotherapy
* HER2 positive disease
* Measurable disease in the breast after diagnostic biopsy, defined as longest diameter ≥ 2.0 cm
* Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry
* Normal bone marrow function
* Normal hepatic function
* Normal renal function
* Subjects must sign an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form before any study specific procedures
* Left ventricular ejection fraction (LVEF) of ≥55% by 2D echocardiogram
* Complete all 4 cycles of run-in chemotherapy
Exclusion Criteria
* Presence of known metastases
* Received prior treatment, including chemotherapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer
* Other concomitant active malignancy or history of malignancy in the past 5 years except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
* Pre-existing clinically significant (≥ grade 2) peripheral neuropathy
* Any history of documented or current congestive heart failure, current high-risk uncontrolled arrhythmias, current angina pectoris requiring a medicinal product, current clinically significant valvular disease, current evidence of transmural infarction on electrocardiogram (ECG), or current poorly controlled hypertension
* Severe dyspnea at rest requiring supplementary oxygen therapy
* History of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV)
* Recent infection requiring a course of systemic anti-infectives that were completed ≤ 14 days before enrollment (with the exception of uncomplicated urinary tract infection)
* Woman of childbearing potential who is pregnant or is breast feeding
* Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, true abstinence \[periodic abstinence (eg calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\], sterilization, or other non-hormonal forms of contraception) during treatment and for at least 7 months after the last administration of the protocol specified treatment
* Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study
* Other investigational procedures while participating in this study are excluded
* Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products, trastuzumab, murine proteins, or to any of the excipients
* Subject previously has enrolled and/or has been randomized in this study
* Subject likely to not be available to complete all protocol required study visits or procedures
* History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actavis Inc.
INDUSTRY
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Brest, , Belarus
Research Site
Grodno, , Belarus
Research Site
Minsk, , Belarus
Research Site
Minsk, , Belarus
Research Site
Salvador, Estado de Bahia, Brazil
Research Site
Ijuí, Rio Grande do Sul, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
Jaú, São Paulo, Brazil
Research Site
Santo André, São Paulo, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Sofia, Sofia, Bulgaria
Research Site
Veliko Tarnovo, Veliko Tarnovo, Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Moncton, New Brunswick, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Temuco, Cautín, Chile
Research Site
Santiago, , Chile
Research Site
Fürstenwalde, Brandenburg, Germany
Research Site
Frankfurt am Main, Hesse, Germany
Research Site
Frankfurt am Main, Hesse, Germany
Research Site
Bonn, North Rhine-Westphalia, Germany
Research Site
Bottrop, North Rhine-Westphalia, Germany
Research Site
Berlin, , Germany
Research Site
Athens, Attica, Greece
Research Site
Athens, Attica, Greece
Research Site
Heraklion, Crete, Greece
Research Site
Thessaloniki, Nea Efkarpia, Greece
Research Site
Debrecen, Hajdú-Bihar, Hungary
Research Site
Szolnok, Jász-Nagykun-Szolnok, Hungary
Research Site
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary
Research Site
Szekszárd, Tolna County, Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
San Fermo della Battaglia, COMO, Italy
Research Site
Bari, , Italy
Research Site
Milan, , Italy
Research Site
Palermo, , Italy
Research Site
Parma, , Italy
Research Site
Piacenza, , Italy
Research Site
Varese, , Italy
Research Site
Toluca, Estado de Mexico, Mexico, Mexico
Research Site
Monterrey, Nuevo León, Mexico
Research Site
San Luis Potosí City, San Luis Potosí, Mexico
Research Site
Querétaro, , Mexico
Research Site
Poznan, Greater Poland Voivodeship, Poland
Research Site
Poznan, Greater Poland Voivodeship, Poland
Research Site
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Research Site
Warszawa, Lublin Voivodeship, Poland
Research Site
Warsaw, Masovian Voivodeship, Poland
Research Site
Warsaw, Masovian Voivodeship, Poland
Research Site
Gdansk, Pomeranian Voivodeship, Poland
Research Site
Rybnik, Silesian Voivodeship, Poland
Research Site
Cluj-Napoca, Cluj, Romania
Research Site
Ploieşti, Prahova, Romania
Research Site
Timișoara, Timiș County, Romania
Research Site
Brasov, , Romania
Research Site
Cluj-Napoca, , Romania
Research Site
Obninsk, Kaluzhskaya, Russia
Research Site
Moscow Region, Moscow, Russia
Research Site
Arkhangelsk, Primorskiy (Maritime) Kray, Russia
Research Site
Saransk, Respublika Mordoviya, Russia
Research Site
Yaroslavl, Yaroslavlr, Russia
Research Site
Chelaybinsk, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Pyatigorsk, , Russia
Research Site
Ryazan, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Sochi, , Russia
Research Site
Belgrade, , Serbia
Research Site
Belgrade, , Serbia
Research Site
Kamenitz, , Serbia
Research Site
Kragujevac, , Serbia
Research Site
Niš, , Serbia
Research Site
Johannesburg, Gauteng, South Africa
Research Site
Durban, KwaZulu-Natal, South Africa
Research Site
Cape Town, Western Cape, South Africa
Research Site
Cape Town, Western Cape, South Africa
Research Site
Sabadell, Barcelona, Spain
Research Site
A Coruña, LA Coruna, Spain
Research Site
Lleida, Lleida, Spain
Research Site
Alcorcón, Madrid, Spain
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Kyiv, Kyiv City, Ukraine
Research Site
Lutsk, Volyn Oblast, Ukraine
Research Site
Uzhhorod, Zakarpattia Oblast, Ukraine
Research Site
Chernivtsi, , Ukraine
Research Site
Dnipropetrovsk, , Ukraine
Research Site
Kharkiv, , Ukraine
Research Site
Lviv, , Ukraine
Research Site
Zaporizhzhya, , Ukraine
Research Site
Nottingham, England, United Kingdom
Research Site
Peterborough, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kolberg HC, Colleoni M, Demetriou GS, Santi P, Tesch H, Fujiwara Y, Tomasevic Z, Hanes V. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. Drug Saf. 2020 Mar;43(3):233-242. doi: 10.1007/s40264-019-00886-3.
von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018 Jul;19(7):987-998. doi: 10.1016/S1470-2045(18)30241-9. Epub 2018 Jun 4.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-004319-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
20120283
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.